Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Pfizer Inc (PFE) vs Under Armour Inc Class A (UA) Price & Performance

Pfizer IncTrade
Under Armour Inc Class ATrade

Price performance (Past 24H)

Key statistics

Pfizer Inc vs Under Armour Inc Class A — how do they compare? Pfizer Inc trades at $27.85 (market cap $158.39B), while Under Armour Inc Class A trades at $4.82 (market cap $2.15B). The key difference: Pfizer Inc is far larger — about 73.7× Under Armour Inc Class A's market cap, and Pfizer Inc pays a 6.19% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals.

PFEUA
Market Cap
$158.39B$2.15B
Volume
29,869,932
Sector
HealthConsumer Cyclical
52-Week High
$29.02$7.88
52-Week Low
$23.60$3.96
Enterprise Value
$209.89B$3.13B
Dividend Yield
6.19%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Pfizer Inc

Pfizer (PFE) trades at $27.78, down 2.36% today, with a consensus price target of $28.33 suggesting modest upside. The stock shows mixed technical signals with bullish moving averages but neutral oscillators. Recent earnings have consistently beaten expectations, though revenue declined from pandemic peaks. The company maintains strong cash flow generation and a solid dividend yield of approximately 3.1%.

Pfizer presents a value opportunity with reasonable valuation metrics and dividend stability, but faces headwinds from post-COVID revenue normalization and patent expirations. The company's pipeline progress in obesity and oncology could drive future growth, though execution risks remain. Analyst sentiment leans cautious with 59% hold ratings.

Under Armour Inc Class A

Under Armour (UA) trades at $4.95, down 3.32% amid bearish technical signals and weak fundamentals. The stock shows negative profitability with a net income margin of -9.99% and declining revenue trends. Recent earnings have been mixed, with Q2 2026 beating expectations but Q1 2026 missing. Cash flow remains negative, and the company faces challenges from softer consumer demand in key markets.

The outlook is cautious due to persistent revenue declines and negative margins. While analyst consensus leans slightly bullish with 40.3% buy ratings, significant risks include execution challenges and competitive pressures. Investors should weigh the potential for a turnaround against ongoing operational headwinds.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Pfizer Inc

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Read more on PFE

About Under Armour Inc Class A

Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.

Read more on UA